Table 3. Findings of recent whole-genome association studies.
Disease | Source | Gene/locus | ORhet | ORhom | P value | PAR (%) |
---|---|---|---|---|---|---|
Breast cancer | Easton et al55 | FGFR2 | 1.20 | 1.64 | 1 × 10−10 | 16 |
Hunter et al56 | FGFR2 | 1.23 | 1.63 | 2 × 10−76 | — | |
TNRC9 | 1.23 | 1.39 | 1 × 10−36 | — | ||
MAP3K1 | 1.13 | 1.27 | 2 × 10−20 | — | ||
LSP1 | 1.06 | 1.17 | 3 × 10−9 | — | ||
8q24 | 1.06 | 1.18 | 5 × 10−12 | — | ||
Stacey et al57 | 2q35 | 1.11 | 1.44 | 5 × 10−14 | 14 | |
TNRC9 | 1.27 | 1.64 | 6 × 10−19 | 13 | ||
Coronary artery disease | McPherson et al58 | 9p21 | 1.20 | — | 4 × 10−6 | 13 |
Myocardial infarction | Helgadottir et al59 | 9p21 | 1.25 | 1.64 | 1 × 10−20 | 21 |
Obesity | Frayling et al60 | FTO | 1.32 | 1.67 | 3 × 10−35 | 20 |
Diabetes | Sladek et al61 | TCF7L2 | 1.65 | 2.77 | 1 × 10−34 | 28 |
SLC30A8 | 1.18 | 1.53 | 6 × 10−8 | 24 | ||
HHEX | 1.19 | 1.44 | 3 × 10−6 | 19 | ||
EXT2 | 1.25 | 1.50 | 1 × 10−4 | 16 | ||
Steinthorsdottir et al62 | CDKAL1 | 1.25 | 1.50 | 8 × 10−9 | 16 | |
Scott et al63 | IGF2BP1 | 1.14 | — | 9 × 10−16 | — | |
CDKN2A/B | 1.20 | — | 8 × 10−15 | — | ||
11p12 | 1.25 | — | 4 × 10−7 | — | ||
Zeggini et al64 | KCNJ11 | 1.14 | — | 5 × 10−11 | — | |
PPARG | 1.14 | — | 2 × 10−14 | — | ||
Prostate cancer | Yeager et al65 | 8q24 | 1.26 | 1.58 | 9 × 10−13 | 21 |
Gudmundsson et al66 | 8q24 | 1.71 | — | 2 × 10−14 | 13 |
Abbreviations: ORhet, odds ratio – heterozygotes; ORhom, odds ratio – homozygotes; ‘—', not reported; PAR, population-attributable risk.
Source: Modified from Topol et al.4 Copyright © 2007 American Medical Association. All rights reserved.